Clarus Wealth Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Clarus Wealth Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$163K	–	136
2021 Q1	$163K	Hold	10,000	–	–	0.1%	127
2020 Q4	$140K	Hold	10,000	–	–	0.09%	128
2020 Q3	$101K	Hold	10,000	–	–	0.08%	122
2020 Q2	$115K	Hold	10,000	–	–	0.1%	123
2020 Q1	$103K	Hold	10,000	–	–	0.1%	111
2019 Q4	$162K	Hold	10,000	–	–	0.11%	134
2019 Q3	$133K	Buy	+10,000	New	+$139K	0.1%	137

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Clarus Wealth Advisors's VNDA Position: Q2 2021 in Review

Clarus Wealth Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q2 2021, closing a stake of 10,000 shares — an estimated $163K sold.

Clarus Wealth Advisors first reported a position in VNDA in Q3 2019 and held it in 7 quarters. The position peaked at $163K in Q1 2021. 181 funds tracked by Wall St. Rank hold VNDA as of Q2 2021.

Clarus Wealth Advisors reported no remaining Vanda Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Clarus Wealth Advisors sold 10,000 Vanda Pharmaceuticals shares in Q2 2021, an estimated $163K.
Clarus Wealth Advisors first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 7 quarters.
Clarus Wealth Advisors's Vanda Pharmaceuticals position peaked at $163K in Q1 2021.
181 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2021.

Based on Clarus Wealth Advisors's 13F filing for Q2 2021, filed 13 Jul 2021.